To shape the strategic goals of the Rare Disease (RD) category by overseeing the development of all pipeline assets in Phase 1 through regulatory approval/pre-launch. This role directly impacts the ability to achieve business objectives on a global basis by providing strategic guidance on funding models for gene therapies and transformative orphan drugs, access scenarios, pricing, patient value and payer evidence. This Senior Director will function with a One PHI mindset and will lead a team of outcomes scientists and access strategists. She/he will join the PHI RD LT to ensure there is a single and coordinated view on strategy and delivery for PHI to the RD business and will collaborate seamlessly with the PHI Center of Excellence. This Senior Director will become a strategic partner to RD Commercial Development, the RD Research Unit, RD Global Product Development as well as Regulatory to develop and implement access strategies and evidence development for developing assets, including gene therapy. Lead Team: Lead the PHI RD pipeline and development team comprised of outcomes scientists and access strategists. Strategic Partnership: Become an active member of the PHI RD LT and a strategic partner to business, GPD, Corporate Affairs and WRD colleagues. Effectively use the Rare Disease Gene Therapy Portfolio Management Team and DAWGs and to monitor the competitive environment, deliver strategy updates as needed, prioritize pipeline programs based on access opportunities and threats. Plan & Deliver on Commitments: Support Public Policy initiatives to develop novel Gene Therapy payment models and communicate the value of genetic medicines. Develop internal and external engagement plan to build, validate and pilot test new pilot models for orphan medicines and gene therapies. Lead the execution of outcomes and access studies and projects (including EJP models, payer, pricing research, all components of the VEST - value evidence suite of tools, etc.) in alignment with cross-functional colleagues to demonstrate the value proposition for assets in the RD pipeline and support critical go/no-go pivotal trial decision making (Phase 2B conditional approval or Phase 3 in PSI). In particular: * Incorporate humanistic and economic endpoints into clinical trials across all phases of product development to build comprehensive trial-based evidence in line with overall strategy for the assets and to ensure global reimbursement and access requirements. Provide strategic input in the selection of relevant patient population and comparators within clinical trials to enable successful negotiations, reimbursement, and appropriate patient access with global payer and regulatory decision makers. * Develop natural history studies to quantify unmet needs in RD patients * Development and validation of new Patient Reported Outcomes measures as appropriate for inclusion in RCTs, registries, and prospective real world studies. * Engage in value consortiums and with HTAs to develop new value frameworks for RD assets * Generate payer insights in global markets through early payer advice, EMA/HTA parallel scientific advice, market research, etc. to inform pricing and access strategies and commercial assessments for various products External Partnerships: Develop strategic partnerships and research collaborations with key external experts, healthcare policy makers, payers, patient advocacy groups and various academic and community settings to support pipeline assets and gene therapies. Shape the external environment to find access pathways across NA, IDM and emerging markets to pay for the new wave of gene therapies. Qualifications: Minimum Masters degree in a healthcare, business or economic field preferred. Knowledge and perience in early drug development. Strong technical knowledge of health economics and financial modeling Minimum 10 years' experience in health outcomes/market access and related fields, 5 of which are as part of global market access in the biopharma industry Experienced in leading cross functional teams and influencing senior leaders in R&D, regulatory, policy with data, insights and research Strong methodological skills in clinical trials, epidemiology, or health services research is required Knowledge and experience in the RD therapeutic area is preferred Experience with HTA organizations such as NICE, SMC, PBAC is desirable Experience with US payers in the assessment of specialty pharmacy products Excellent interpersonal skills required: ability to understand and respond to multiple internal and external customers; build strategic partnerships internally and externally Excellent oral and written English communication skills required Demonstrated ability to manage multiple projects (multitask) involving complex processes, significant budget, competing deadlines and rapidly shifting priorities Ability to influence key members of scientific and commercial teams constructively and without conflict Skilled in functioning within a matrix organization where managing through influence is required Ability to travel internationally Four direct reports (outcomes scientists and access strategists) Matrixed strategic partnership and project leadership required EEO & Employment Eligibility Pfizer is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Pfizer also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Pfizer is an E-Verify employer. Sunshine Act Pfizer reports payments and other transfers of value to health care providers as required by federal and state transparency laws and implementing regulations. These laws and regulations require Pfizer to provide government agencies with information such as a health care provider's name, address and the type of payments or other value received, generally for public disclosure. Subject to further legal review and statutory or regulatory clarification, which Pfizer intends to pursue, reimbursement of recruiting expenses for licensed physicians may constitute a reportable transfer of value under the federal transparency law commonly known as the Sunshine Act. Therefore, if you are a licensed physician who incurs recruiting expenses as a result of interviewing with Pfizer that we pay or reimburse, your name, address and the amount of payments made currently will be reported to the government. If you have questions regarding this matter, please do not hesitate to contact your Talent Acquisition representative. Additional Offer Details: - - Eligible for Relocation Package YES - Eligible for Employee Referral Bonus Yes Pfizer is an equal opportunity employer and complies with all applicable equal employment opportunity legislation in each jurisdiction in which it operates.

Apply For This Job